Nystatin Oral Suspension Articles
Actelion’s Tracleer gets US label extension
10 August 2009
Boehringer Ingelheim to start Ph II study with Tovok
4 August 2009
AEterna buys AEZS-130 from Ardana for $232K
9 June 2009
Bayer reports further riociguat data at ATS
3 June 2009
FDA does not ask for new rivaroxaban trials
3 June 2009
Amarillo enrolls 60 in Ph II interferon study
1 June 2009
Tracleer plus tadalafil boosts 6MWD
28 May 2009
HRA Pharma's ellaOne cleared across Europe
28 May 2009
FDA grants full approval to B-MS' Sprycel
27 May 2009
Amgen pays $50M to option Cytokinetics' HF drug
26 May 2009
AnaMar initiates clinical trials of oral RA drug
22 May 2009
Novartis gets option to acquire Elixir
22 May 2009
Daiichi Sakyo presents Evista compliance data
20 May 2009
Wyeth accused of overcharging Medicaid
19 May 2009
Further 318 generics added to Japan's NHI list
19 May 2009
Tarceva improves PFS 41% in advanced NSCLC
18 May 2009
Nycomed submits Daxas for EMEA appro
18 May 2009
Sutent recommended as UK 1st-line mRCC drug
18 May 2009
P&G wins patent infringement case over Actonel
15 May 2009
Elderly Xeloda patients "twice as likely to die"
15 May 2009
Bayer begins European roll-out of Qlaira
14 May 2009
Novo Nordisk's Levemir lowers ave blood sugar
14 May 2009
ActoGeniX gets nod for oral mucosits trial
14 May 2009
Stock Commentary - Europe - week to may 11, 2009
14 May 2009
Vivus updates of ED drug avanafil
13 May 2009
Xarelto more effective than enoxaparin in VTE
11 May 2009
Ergomed teams with Genzyme for oncology drug
7 May 2009
German Merck cancer drug may treat MS
1 May 2009
Bayer hit by charges and falling material science sales in 1st qtr, but pharma division doing well
29 April 2009
Pharming's Prodarsan gets US orphan status
28 April 2009
Bayer and Onyx halt Nexavar trial
28 April 2009
FDA delays AZ/B-MS Onglyza NDA review
28 April 2009
Transgene's HCV vacc to enter Ph II in 2010
27 April 2009
Vertex' telaprevir achieves unprecedented SVR
27 April 2009
Merck & Co signs performance-based contract with CIGNA
24 April 2009
Positive preclinical data on Idenix HCV drugs
24 April 2009
Salix reports strong Ph III data for rifaximin in HE
24 April 2009
Phytopharm begins PD study with oral Cogane
24 April 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
SpePharma launhces Xerotin and MuGard in Europe
23 April 2009
Low-cost cholera vacc developed by IVI
22 April 2009
Medarex in up to $225M C. diff deal with Merck & Co
22 April 2009
Merck & Co 1st-qtr profit slumps 57%
21 April 2009
Phytopharm's Cogane enters Ph I PK study
20 April 2009
Cochrane Review calls for more R&D on ORS
17 April 2009
Post-op patients on EPA maintain body weight
17 April 2009
FDA OKs unapproved opioid due to shortage
16 April 2009
Ensemble enters R&D alliance with B-MS
16 April 2009
Pro-Pharma drug prevents mucositis
16 April 2009
Amarillo supplies interferon for Australian flu study
16 April 2009
Japan stock market week to April 13, 2009
14 April 2009
Aclasta more effective than risedronate
14 April 2009
Alkermes' addiction drug to enter Ph II in 2H
9 April 2009
UPDATE: Helsinn to set up R&D center in Ireland
9 April 2009
Novartis' Coartem approved by FDA
9 April 2009
Daiichi/Lilly's Efient gets first world launch in UK - first new antiplatelet drug in a decade
9 April 2009
CyDex Pharma IP to be auctioned
8 April 2009
Shionogi begins European Ph I testing of cancer drug
8 April 2009
Cobra's oral vacc platform supported in anthrax
6 April 2009
Pfizer's R&D pipeline down 12% on six months ago as part of new focus high-priority areas
3 April 2009
GSK files to expand Tyverb use in USA & EU
3 April 2009
Teva gets FDA appro for generic Yaz
3 April 2009
Repligen licenses rights for bipolar therapy
2 April 2009
FDA blocks unapproved narcotics marketing
1 April 2009
EMD Serono to open new US research lab
1 April 2009
Ralfinamide enters Ph IIb/III study in NLBP
1 April 2009
Bavaria Ind acquires Catalent's business
1 April 2009
Aspirin more effective with Plavix in AF
1 April 2009
AZD0837 "comparable" profile to VKAs in Ph II study
30 March 2009
Cosmo's 2008 profit jumps 5.2% to $12.9M
30 March 2009
Pradaxa Ph III stroke program nears end
30 March 2009
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
